mpc

MPC-0767, a potent, selective, and orally active hsp90 inhibitor, is the L-alanine ester prodrug of MPC-3100, exhibiting enhanced chemical stability.

MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of Hsp90 with significant antitumor activity [1].

Verubulin hydrochloride (MPC-6827 hydrochloride) is a blood-brain barrier permeable microtubule-disrupting agent with potent and broad-spectrum cytotoxic activities and significant anticancer efficacy in human MX-1 breast cancer and various mouse xenograft cancer models.

Bevirimat (PA-457) is a first-in-class inhibitor of HIV-1 maturation, blocking the cleavage of the Gag capsid (CA) precursor, CA-SPI, to mature CA protein during virion maturation.

Verubulin (MPC 6827) is a potent microtubule blocker with cytotoxic and potentially anticancer activity that disrupts newly formed blood vessels in xenografts, and can be used to image microtubules (MTs) using positron emission tomography (PET).

MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). This compound, MSDC-0602K, has potential applications in researching fatty liver conditions, including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K acts as an insulin sensitizer, improving insulinemia and fatty liver disease in mice both individually and in combination with Liraglutide.

AMPC, a powerful and efficient inhibitor of TFF3, demonstrates inhibitory effects on cell proliferation, survival, oncogenicity, and CSC-like behavior in TFF3-positive CMS4 CRC cells. It acts as a promising standalone anti-cancer agent and also enhances the effects of 5-FU when used in combination, making it a valuable tool for cancer research.

EDMPC, a cationic lipid, exhibits an enhanced capability for DNA delivery to pulmonary tissues. It facilitates intralobar DNA transfer in rodents [1].

Cyclic HPMPC is a potent antiviral agent that increases arterial oxygen saturation in mice infected with the lethal vaccinia virus (IHD strain) and reduces viral replication in guinea pigs, thereby improving outcomes in congenital guinea pig cytomegalovirus (GPCMV) infection [1] [2].

PIMPC, a compound endowed with antioxidant and metal-chelating properties, acts as a novel inhibitor of glycogen synthase kinase 3 (GSK-3), and exhibits potential therapeutic effects for Alzheimer's disease [1].

MPCI is a selective melanocortin-4 receptor antagonist.

AMPCP is an Ecto-5'-nucleotidase (CD73) inhibitor.

MSDC 0160 (CAY10415) is a prototype mTOT-modulating insulin sensitizer being used in trials studying the treatment of Type 2 Diabetes and Alzheimer's Disease.

Azemiglitazone (MSDC 0602) is an insulin sensitizer potentially for the treatment of diabetes.

Aranidipine (MPC1304) (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.

UK-5099 (PF-1005023) is a specific and potent inhibitor of MPC carrier activity, effectively inhibiting pyruvate-dependent oxygen consumption in rat heart mitochondria with an IC50 of 50 nM [1].

GW604714X (2,4-Thiazolidinedione, 5-[[5-[6-(4-acetyl-1-piperazinyl)-3-nitro-2-pyridinyl]-2-fluorophenyl]methylene]-) were found to be potent inhibitors of mitochondrial respiration supported by pyruvate

Tarenflurbil ((R)-Flurbiprofen) is the non-cyclooxygenase inhibiting R-enantiomer of the NSAID flurbiprofen, evaluated as a treatment for Alzheimer's disease.